Mirvetuximab soravtansine (MIRV; Elahere; AbbVie) demonstrated significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer, showing particular promise in ...

The main market opportunities in the RSV prophylaxis field lie in the development of new monoclonal antibodies and vaccines, with substantial growth expected due to late-stage pipeline products. This ...

BRITS are being urged to look out for symptoms of RSV after an increase in cases of the highly contagious disease. The virus ...

People aged 75 to 79, as well as people who turned 80 after 1 September 2024, are eligible for a vaccine to protect against respiratory syncytial virus (RSV). RSV affects the airways and lungs and can ...

Providing year-round access to RSV immunization would minimize the risk of large seasonal outbreaks across the nation, ...

Today’s round of questions, my smart-aleck replies and the real answers: Question: Our tax dollars at work? For the past ...

Background Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections (ALRI) among under-5 ...

Invivyd (IVVD) identified and nominated for preclinical development a monoclonal antibody candidate for the prevention of Respiratory Syncytial ...

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from ...

The Kansas wastewater monitoring program has a new KDHE dashboard where you can see respiratory virus trends in Topeka for ...

As the colder weather months begin, respiratory viruses like the common cold, the flu, RSV and COVID-19, become more ...